Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Daveri, Elena ^a   Valacchi, Giuseppe ^b   Romagnoli, Roberta ^a   Maellaro, Emilia ^a   Maioli, Emanuela ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; ROTTLERIN;

ARTICLE; CANCER INCIDENCE; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84935835351     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/545838     Document Type: Article

References (42)

1. H. Davies, G. R. Bignell, C. Cox et al., "Mutations of the BRAF gene in human cancer," Nature, vol. 417, no. 6892, pp. 949-954, 2002.
2. R. Houben, J. C. Becker, A. Kappel et al., "Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis," Journal of Carcinogenesis, vol. 3, article 6, 2004.
3. J. Yang, S. Zaja-Milatovic, Y.-M. Thu, F. Lee, R. Smykla, and A. Richmond, "Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy," Molecular Cancer Therapeutics, vol. 8, no. 3, pp. 636-647, 2009.
4. R. Kumar, S. Angelini, E. Snellman, and K. Hemminki, "BRAF mutations are common somatic events in melanocytic nevi," Journal of InvestigativeDermatology, vol. 122, no. 2, pp. 342-348, 2004.
5. P. M. Pollock, U. L. Harper, K. S. Hansen et al., "High frequency of BRAF mutations in nevi," Nature Genetics, vol. 33, no. 1, pp. 19-20, 2003.
6. G. Palmieri, M. Capone, M. L. Ascierto et al., "Main roads to melanoma," Journal of TranslationalMedicine, vol. 7, article 86, 2009.
7. R. Nazarian, H. Shi, Q. Wang et al., "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation," Nature, vol. 468, no. 7326, pp. 973-977, 2010.
8. N. Wagle, E. M. Van Allen, D. J. Treacy et al., "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition," Cancer Discovery, vol. 4, no. 1, pp. 61-68, 2014.
9. A. Sewing, B. Wiseman, A. C. Lloyd, and H. Land, "Highintensity Raf signal causes cell cycle arrestmediated by p21Cip1," Molecular and Cellular Biology, vol. 17, no. 9, pp. 5588-5597, 1997.
10. S.-J. Cozzi, P. G. Parsons, S. M. Ogbourne, J. Pedley, and G. M. Boyle, "Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway," Cancer Research, vol. 66, no. 20, pp. 10083-10091, 2006.
11. V. Fortino, C. Torricelli, E. Capurro, G. Sacchi, G. Valacchi, and E. Maioli, "Antiproliferative and survival properties of PMA in MCF-7 breast cancer cell," Cancer Investigation, vol. 26, no. 1, pp. 13-21, 2008.
12. F. G. Haluska, H. Tsao, H. Wu, F. S. Haluska, A. Lazar, and V. Goel, "Genetic alterations in signaling pathways in melanoma," Clinical Cancer Research, vol. 12, no. 7, 2006.
13. T. Haapajarvi, K. Pitkanen, and M. Laiho, "Human melanoma cell lineUVresponses showindependency of p53 function," Cell Growth and Differentiation, vol. 10, no. 3, pp. 163-171, 1999.
14. R. Prasad and S. K. Katiyar, "Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein," Oncotarget, vol. 5, no. 21, pp. 10636-10649, 2014.
15. H. Wu, V. Goel, and F. G. Haluska, "PTEN signaling pathways in melanoma," Oncogene, vol. 22, no. 20, pp. 3113-3122, 2003.
16. J. Utikal, M. Udart, U. Leiter, R. U. Peter, and G. Krahn, "Additional Cyclin D1 gene copies associated with chromosome aberrations in cutaneousmalignantmelanoma," International Journal of Oncology, vol. 26, no. 3, pp. 597-605, 2005.
17. E. Maioli, C. Torricelli, and G. Valacchi, "Rottlerin and cancer: novel evidence and mechanisms," The Scientific World Journal, vol. 2012, Article ID350826, 11 pages, 2012.
18. D. Zhang, V. Anantharam, A. Kanthasamy, and A. G. Kanthasamy, "Neuroprotective effect of protein kinase Cδ inhibitor rottlerin in cell culture and animal models of Parkinson's disease," Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 3, pp. 913-922, 2007.
19. I. Ohno, G. Eibl, I. Odinokova et al., "Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family," The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 298, no. 1, pp. G63-G73, 2010.
20. S. P. Davies, H. Reddy, M. Caivano, and P. Cohen, "Specificity and mechanism of action of some commonly used protein kinase inhibitors," Biochemical Journal, vol. 351, no. 1, pp. 95-105, 2000.
21. J.-F. Liu, M. Crepin, J.-M. Liu, D. Barritault, and D. Ledoux, "FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway," Biochemical and Biophysical Research Communications, vol. 293, no. 4, pp. 1174-1182, 2002.
22. F. Gaubert, F. Escaffit, C. Bertrand et al., "Expression of the highmolecular weight fibroblast growth factor-2 isoformof 210 amino acids is associated with modulation of protein kinases C delta and epsilon and ERK activation,"The Journal of Biological Chemistry, vol. 276, no. 2, pp. 1545-1554, 2001.
23. M. Karin, "Nuclear factor-κB in cancer development and progression," Nature, vol. 441, no. 7092, pp. 431-436, 2006.
24. C. Torricelli, V. Fortino, E. Capurro et al., "Rottlerin inhibits the nuclear factor kappaB/cyclin-D1 cascade in MCF-7 breast cancer cells," Life Sciences, vol. 82, no. 11-12, pp. 638-643, 2008.
25. E. Maioli, L. Greci, K. Soucek et al., "Rottlerin inhibits ROS formation and prevents NFκB activation in MCF-7 and HT-29 cells," Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 742936, 7 pages, 2009.
26. Y. Ueda and A. Richmond, "NF-κB activation in melanoma," Pigment Cell Research, vol. 19, no. 2, pp. 112-124, 2006.
27. C. Torricelli, E. Daveri, S. Salvadori et al., "Phosphorylationindependent mTORC1 inhibition by the autophagy inducer Rottlerin," Cancer Letters, vol. 360, no. 1, pp. 17-27, 2015.
28. G. Valacchi, A. Pecorelli, C. Sticozzi et al., "Rottlerin exhibits antiangiogenic effects in vitro," Chemical Biology and Drug Design, vol. 77, no. 6, pp. 460-470, 2011.
29. G. Valacchi, A. Pecorelli, M. Mencarelli et al., "Rottlerin: a multifaced regulator of keratinocyte cell cycle," Experimental Dermatology, vol. 18, no. 6, pp. 516-521, 2009.
30. V. Sharma, "A polyphenolic compound rottlerin demonstrates significant in vitro cytotoxicity against human cancer cell lines: isolation and characterization from the fruits of Mallotus philippinensis," Journal of PlantBiochemistryandBiotechnology, vol. 20, no. 2, pp. 190-195, 2011.
31. M. Huang, S. N. Tang, G. Upadhyay et al., "Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated fromKras(G12D) mice," Cancer Letters, vol. 353, no. 1, pp. 32-40, 2014.
32. C. Torricelli, S. Salvadori, G. Valacchi et al., "Alternative pathways of cancer cell death by rottlerin: apoptosis versus autophagy," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 980658, 11 pages, 2012.
33. D. C. Guttridge, C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. Baldwin Jr., "NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1," Molecular and Cellular Biology, vol. 19, no. 8, pp. 5785-5799, 1999.
34. D. Nagata, E. Suzuki, H. Nishimatsu et al., "Transcriptional activation of the cyclin D1 gene is mediated by multiple ciselements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells," The Journal of Biological Chemistry, vol. 276, no. 1, pp. 662-669, 2001.
35. K. Balmanno and S. J. Cook, "Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells," Oncogene, vol. 18, no. 20, pp. 3085-3097, 1999.
36. J. Milanini-Mongiat, J. Pouyssegur, and G. Pages, "Identification of two Sp1 phosphorylation sites for p42/p44 mitogenactivated protein kinases: their implication in vascular endothelial growth factor gene transcription," Journal of Biological Chemistry, vol. 277, no. 23, pp. 20631-20639, 2002.
37. G. J. Schouten, A. C. O. Vertegaal, S. T. Whiteside et al., " IκBα is a target for the mitogen-activated 90 kDa ribosomal S6 kinase," The EMBO Journal, vol. 16, no. 11, pp. 3133-3144, 1997.
38. O. N. Ozes, L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner, "NF-κB activation by tumour necrosis factor requires tie Akt serine-threonine kinase," Nature, vol. 401, no. 6748, pp. 82-85, 1999.
39. W. Ouyang, J. Li, Q. Ma, and C. Huang, "Essential roles of PI-3K/Akt/IKKβ/NFκB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells," Carcinogenesis, vol. 27, no. 4, pp. 864-873, 2006.
40. G. Zeng, J. Liu, H. Chen et al., "Dihydromyricetin induces cell cycle arrest and apoptosis in melanoma SK-MEL-28 cells," Oncology Reports, vol. 31, no. 6, pp. 2713-2719, 2014.
41. N. M. Fofaria, S.-H. Kim, and S. K. Srivastava, "Piperine causes G1 phase cell cycle arrest and apoptosis in melanoma cells through checkpoint kinase-1 activation," PLoS ONE, vol. 9, no. 5, Article ID e94298, 2014.
42. J. J. Wang, W. Zhang, and B. J. S. Sanderson, "Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 Cell Line," BioMed Research International, vol. 2013, Article ID 715603, 10 pages, 2013.